Atherothrombosis and the NLRP3 Inflammasome – Endogenous Mechanisms of Inhibition

Recently, the CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) showed the successful anti-inflammatory benefit of canakinumab, a monoclonal antibody targeting interleukin-1 ß (IL-1ß) towards major cardiovascular events (MACE) in patients with a previous myocardial infarction. The magnitude of reduction in MACE was directly attributed to a reduction witnessed in IL-6 and CRP and highlighted the therapeutic potential of selectively targeting IL-1ß for atherosclerotic disease, a notion previously introduced in animal models.
Source: Translational Research - Category: Research Authors: Tags: Review Article Source Type: research